Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT03691376 Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Platinum-Sensit...
Platinum-Sensit...
Platinum-Sensit...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Refractory Fall...
Refractory Ovar...
Refractory Prim...
Aldesleukin
Autologous NY-E...
Cellular Therap...
Melphalan
18 Years - Roswell Park Cancer Institute View A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma NCT00671788 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Dasatinib
Laboratory Biom...
18 Years - GOG Foundation View Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer NCT02996825 Recurrent Breas...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Recurrent Uteri...
Triple-Negative...
Gemcitabine
Gemcitabine Hyd...
Laboratory Biom...
Mirvetuximab So...
Pharmacological...
- City of Hope Medical Center View Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02839707 Fallopian Tube ...
Ovarian High Gr...
Ovarian Seromuc...
Primary Periton...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Plati...
Recurrent Plati...
Recurrent Plati...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Atezolizumab
Bevacizumab
Computed Tomogr...
Pegylated Lipos...
Quality-of-Life...
18 Years - National Cancer Institute (NCI) View Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04781088 Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Recurrent Endom...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Lenvatinib
Paclitaxel
Pembrolizumab
18 Years - Ohio State University Comprehensive Cancer Center View Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT01074411 Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Serous ...
Ovarian Transit...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
Undifferentiate...
Bortezomib
Carboplatin
Laboratory Biom...
Pharmacological...
18 Years - National Cancer Institute (NCI) View Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02446600 Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Prima...
Biospecimen Col...
Carboplatin
Cediranib Malea...
Computed Tomogr...
Echocardiograph...
Gemcitabine
Gemcitabine Hyd...
Laboratory Biom...
Magnetic Resona...
Multigated Acqu...
Olaparib
Paclitaxel
Pegylated Lipos...
Pharmacological...
Quality-of-Life...
18 Years - National Cancer Institute (NCI) View Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT03586661 Deleterious BRC...
Deleterious BRC...
Endometrial Ade...
High Grade Ovar...
Platinum-Resist...
Primary Periton...
Progressive Dis...
Recurrent Endom...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Copanlisib
Niraparib
18 Years - M.D. Anderson Cancer Center View Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02901899 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Guadecitabine
Laboratory Biom...
Pembrolizumab
18 Years - Northwestern University View Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer NCT05672095 Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Biopsy
Biospecimen Col...
Niraparib
Questionnaire A...
Selenium
18 Years - City of Hope Medical Center View Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent NCT02470559 Malignant Ovari...
Malignant Ovari...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Aldesleukin
HER2Bi-Armed Ac...
Laboratory Biom...
Sargramostim
18 Years - Barbara Ann Karmanos Cancer Institute View Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy NCT01492920 Fatigue
Malignant Ovari...
Neuropathy
Neurotoxicity S...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Serous ...
Pain
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Acetyl-L-Carnit...
Placebo
Questionnaire A...
Quality-of-Life...
18 Years - GOG Foundation View Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02315430 Fallopian Tube ...
Ovarian Clear C...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Cabozantinib S-...
Laboratory Biom...
18 Years - National Cancer Institute (NCI) View A Study of FRaDCs for Ovarian Cancer NCT05920798 Fallopian Tube ...
Primary Periton...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Biopsy
Biospecimen Col...
Computed Tomogr...
Magnetic Resona...
Multi-epitope F...
Pembrolizumab
Pheresis
18 Years - Mayo Clinic View TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer NCT01294293 Malignant Ovari...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Serous ...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
TLR8 Agonist VT...
Diagnostic Labo...
Pharmacological...
Pegylated Lipos...
Paclitaxel
18 Years - GOG Foundation View A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer NCT04092270 Endometrial Hig...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
FIGO Grade 1 En...
FIGO Grade 2 En...
Ovarian High Gr...
Ovarian Seromuc...
Ovarian Undiffe...
Platinum-Sensit...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Recurrent Fallo...
Recurrent Low G...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Prima...
Recurrent Prima...
Biospecimen Col...
Computed Tomogr...
Echocardiograph...
Magnetic Resona...
Multigated Acqu...
Pegylated Lipos...
Peposertib
18 Years - National Cancer Institute (NCI) View Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer NCT01720173 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Dalantercept
Laboratory Biom...
18 Years - GOG Foundation View Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT01074411 Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Serous ...
Ovarian Transit...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
Undifferentiate...
Bortezomib
Carboplatin
Laboratory Biom...
Pharmacological...
18 Years - National Cancer Institute (NCI) View Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT01540565 BRCA1 Mutation ...
BRCA2 Mutation ...
Ovarian Epithel...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Laboratory Biom...
Veliparib
18 Years - National Cancer Institute (NCI) View Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer NCT01010126 Adult Hepatocel...
Advanced Adult ...
Endometrial Ser...
Localized Non-R...
Lung Carcinoid ...
Malignant Pancr...
Malignant Pancr...
Malignant Pancr...
Malignant Pancr...
Metastatic Dige...
Ovarian Carcino...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Pancreatic Alph...
Pancreatic Beta...
Pancreatic Delt...
Pancreatic G-Ce...
Pancreatic Poly...
Recurrent Adult...
Recurrent Diges...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Pancr...
Recurrent Prima...
Recurrent Uteri...
Regional Digest...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIA Uter...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIB Uter...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IIIC Uter...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Stage IVA Uteri...
Stage IVB Uteri...
Uterine Carcino...
Bevacizumab
Temsirolimus
18 Years - National Cancer Institute (NCI) View Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer NCT02996825 Recurrent Breas...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Recurrent Uteri...
Triple-Negative...
Gemcitabine
Gemcitabine Hyd...
Laboratory Biom...
Mirvetuximab So...
Pharmacological...
- City of Hope Medical Center View Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02923739 Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Ovari...
Ovarian Adenoca...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Bevacizumab
Emactuzumab
Laboratory Biom...
Paclitaxel
Pharmacological...
18 Years - M.D. Anderson Cancer Center View Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT03026062 Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Refractory Fall...
Refractory Ovar...
Refractory Prim...
Durvalumab
Tremelimumab
18 Years - M.D. Anderson Cancer Center View Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers NCT06295965 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Non-Interventio...
- University of Washington View Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02101775 Ovarian Brenner...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Serous ...
Ovarian Undiffe...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Adavosertib
Gemcitabine Hyd...
Laboratory Biom...
Pharmacological...
Placebo Adminis...
Questionnaire A...
18 Years - National Cancer Institute (NCI) View Collecting Tumor Samples From Patients With Gynecological Tumors NCT00897442 Borderline Ovar...
Borderline Ovar...
Cervical Adenoc...
Cervical Adenos...
Cervical Small ...
Cervical Squamo...
Childhood Embry...
Childhood Malig...
Endometrioid St...
Gestational Tro...
Malignant Mesot...
Malignant Ovari...
Melanoma
Neoplasm of Unc...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Serous ...
Paget Disease o...
Recurrent Cervi...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Prima...
Recurrent Uteri...
Recurrent Vagin...
Recurrent Vulva...
Stage I Ovarian...
Stage I Uterine...
Stage I Vaginal...
Stage I Vulvar ...
Stage IA Cervic...
Stage IA Fallop...
Stage IA Ovaria...
Stage IA Ovaria...
Stage IB Cervic...
Stage IB Fallop...
Stage IB Ovaria...
Stage IB Ovaria...
Stage IC Fallop...
Stage IC Ovaria...
Stage IC Ovaria...
Stage II Ovaria...
Stage II Uterin...
Stage II Vagina...
Stage II Vulvar...
Stage IIA Cervi...
Stage IIA Fallo...
Stage IIA Ovari...
Stage IIA Ovari...
Stage IIB Cervi...
Stage IIB Fallo...
Stage IIB Ovari...
Stage IIB Ovari...
Stage IIC Fallo...
Stage IIC Ovari...
Stage IIC Ovari...
Stage III Borde...
Stage III Cervi...
Stage III Uteri...
Stage III Vagin...
Stage III Vulva...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Border...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Stage IV Uterin...
Stage IVA Cervi...
Stage IVA Vagin...
Stage IVB Cervi...
Stage IVB Vagin...
Stage IVB Vulva...
Uterine Corpus ...
Uterine Corpus ...
Vulvar Squamous...
Laboratory Biom...
- GOG Foundation View Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT05564377 Advanced Malign...
Anatomic Stage ...
Anatomic Stage ...
Locally Advance...
Malignant Femal...
Metastatic HER2...
Metastatic Mali...
Recurrent Endom...
Recurrent Fallo...
Recurrent Malig...
Recurrent Malig...
Recurrent Ovari...
Recurrent Prima...
Unresectable HE...
Unresectable Ma...
Alpelisib
Binimetinib
Biopsy
Biospecimen Col...
Bone Marrow Asp...
Bone Scan
Computed Tomogr...
Echocardiograph...
Fluorouracil
Fulvestrant
Ipatasertib
Leucovorin
Magnetic Resona...
Multigated Acqu...
Mutation Carrie...
Neratinib Malea...
Nilotinib Hydro...
Olaparib
Oxaliplatin
Paclitaxel
Palbociclib
Panitumumab
Positron Emissi...
Selumetinib Sul...
Sotorasib
- National Cancer Institute (NCI) View Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02627443 Metastatic Fall...
Metastatic Ovar...
Metastatic Prim...
Ovarian Endomet...
Ovarian High Gr...
Platinum-Sensit...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Berzosertib
Carboplatin
Gemcitabine Hyd...
Laboratory Biom...
Pharmacological...
18 Years - National Cancer Institute (NCI) View Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer NCT01716715 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Cabozantinib S-...
Laboratory Biom...
Paclitaxel
18 Years - National Cancer Institute (NCI) View Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study NCT00968799 Epithelial Ovar...
Fallopian Tube ...
Hyperthermic in...
Cytoreduction
Cisplatin
18 Years - 70 Years Cantonal Hospital of St. Gallen View Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers NCT05691504 Advanced Endome...
Metastatic Endo...
Metastatic Fall...
Metastatic Plat...
Metastatic Prim...
Recurrent Endom...
Recurrent Fallo...
Recurrent Plati...
Recurrent Prima...
Stage III Uteri...
Stage IV Uterin...
Biopsy
Biospecimen Col...
Cobimetinib
Computed Tomogr...
Echocardiograph...
Magnetic Resona...
Multigated Acqu...
Pelcitoclax
18 Years - National Cancer Institute (NCI) View Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer NCT02283658 Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Serous ...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
Everolimus
Laboratory Biom...
Letrozole
18 Years - Mayo Clinic View Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04387227 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Carboplatin
Pembrolizumab
Computed Tomogr...
Magnetic Resona...
Biospecimen Col...
18 Years - University of Washington View Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer NCT02111941 Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Undifferentiate...
Undifferentiate...
Laboratory Biom...
Multi-epitope F...
18 Years - Mayo Clinic View p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer NCT02275039 Recurrent Ovari...
Recurrent Fallo...
Recurrent Prima...
modified vaccin...
gemcitabine hyd...
laboratory biom...
18 Years - City of Hope Medical Center View Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy NCT00602277 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Laboratory Biom...
Wild-type Reovi...
18 Years - National Cancer Institute (NCI) View Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial NCT05554328 Recurrent Endom...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Biopsy
Biospecimen Col...
Bone Marrow Asp...
Computed Tomogr...
Echocardiograph...
Multigated Acqu...
Olaparib
Selumetinib Sul...
18 Years - National Cancer Institute (NCI) View Collecting Tumor Samples From Patients With Gynecological Tumors NCT00897442 Borderline Ovar...
Borderline Ovar...
Cervical Adenoc...
Cervical Adenos...
Cervical Small ...
Cervical Squamo...
Childhood Embry...
Childhood Malig...
Endometrioid St...
Gestational Tro...
Malignant Mesot...
Malignant Ovari...
Melanoma
Neoplasm of Unc...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Serous ...
Paget Disease o...
Recurrent Cervi...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Prima...
Recurrent Uteri...
Recurrent Vagin...
Recurrent Vulva...
Stage I Ovarian...
Stage I Uterine...
Stage I Vaginal...
Stage I Vulvar ...
Stage IA Cervic...
Stage IA Fallop...
Stage IA Ovaria...
Stage IA Ovaria...
Stage IB Cervic...
Stage IB Fallop...
Stage IB Ovaria...
Stage IB Ovaria...
Stage IC Fallop...
Stage IC Ovaria...
Stage IC Ovaria...
Stage II Ovaria...
Stage II Uterin...
Stage II Vagina...
Stage II Vulvar...
Stage IIA Cervi...
Stage IIA Fallo...
Stage IIA Ovari...
Stage IIA Ovari...
Stage IIB Cervi...
Stage IIB Fallo...
Stage IIB Ovari...
Stage IIB Ovari...
Stage IIC Fallo...
Stage IIC Ovari...
Stage IIC Ovari...
Stage III Borde...
Stage III Cervi...
Stage III Uteri...
Stage III Vagin...
Stage III Vulva...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Border...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Stage IV Uterin...
Stage IVA Cervi...
Stage IVA Vagin...
Stage IVB Cervi...
Stage IVB Vagin...
Stage IVB Vulva...
Uterine Corpus ...
Uterine Corpus ...
Vulvar Squamous...
Laboratory Biom...
- GOG Foundation View MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer NCT02068794 Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Ovari...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Laboratory Biom...
Mesenchymal Ste...
Oncolytic Measl...
18 Years - Mayo Clinic View PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02948101 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Anti-CSF1 Monoc...
Cyclophosphamid...
Laboratory Biom...
18 Years - M.D. Anderson Cancer Center View Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT03029598 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Carboplatin
Laboratory Biom...
Pembrolizumab
18 Years - University of Washington View Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients NCT04213794 Malignant Abdom...
Malignant Pelvi...
Recurrent Colon...
Recurrent Desmo...
Recurrent Fallo...
Recurrent Gastr...
Recurrent Lipos...
Recurrent Malig...
Recurrent Ovari...
Recurrent Prima...
Recurrent Recta...
Recurrent Rhabd...
Recurrent Sarco...
Refractory Colo...
Refractory Desm...
Refractory Fall...
Refractory Gast...
Refractory Lipo...
Refractory Mali...
Refractory Ovar...
Refractory Prim...
Refractory Rect...
Refractory Rhab...
Refractory Sarc...
Resectable Lipo...
Resectable Mali...
Resectable Sarc...
Cisplatin
Cytoreductive S...
Doxorubicin
Hyperthermic In...
Sodium Thiosulf...
Computed Tomogr...
Magnetic Resona...
Positron Emissi...
Biospecimen Col...
1 Year - 25 Years Mayo Clinic View A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer NCT01283035 Ovarian Sarcoma
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Akt Inhibitor M...
Laboratory Biom...
18 Years - National Cancer Institute (NCI) View Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT00888615 Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Elesclomol Sodi...
Paclitaxel
18 Years - GOG Foundation View Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02315430 Fallopian Tube ...
Ovarian Clear C...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Cabozantinib S-...
Laboratory Biom...
18 Years - National Cancer Institute (NCI) View Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02627443 Metastatic Fall...
Metastatic Ovar...
Metastatic Prim...
Ovarian Endomet...
Ovarian High Gr...
Platinum-Sensit...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Berzosertib
Carboplatin
Gemcitabine Hyd...
Laboratory Biom...
Pharmacological...
18 Years - National Cancer Institute (NCI) View Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers NCT03968406 Malignant Femal...
Recurrent Cervi...
Recurrent Endom...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Recurrent Vagin...
Stage IV Cervic...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Stage IV Uterin...
Stage IV Vagina...
Stage IVA Cervi...
Stage IVA Fallo...
Stage IVA Ovari...
Stage IVA Prima...
Stage IVA Uteri...
Stage IVA Vagin...
Stage IVB Cervi...
Stage IVB Fallo...
Stage IVB Ovari...
Stage IVB Prima...
Stage IVB Uteri...
Stage IVB Vagin...
Quality-of-Life...
Radiation Thera...
Talazoparib
18 Years - M.D. Anderson Cancer Center View TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors NCT02142803 Adult Glioblast...
Endometrial Cle...
Endometrial Ser...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Serous ...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Recurrent Uteri...
Solid Neoplasm
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Bevacizumab
Laboratory Biom...
Pharmacological...
Sapanisertib
18 Years - National Cancer Institute (NCI) View Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT03029598 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Carboplatin
Laboratory Biom...
Pembrolizumab
18 Years - University of Washington View Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer NCT05231122 Ovarian Clear C...
Platinum-Sensit...
Recurrent Endom...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Plati...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Anti-CD40 Agoni...
Bevacizumab
Pembrolizumab
Quality-of-Life...
Questionnaire A...
18 Years - Roswell Park Cancer Institute View Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer NCT01264432 Adult Solid Neo...
Peritoneal Carc...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Laboratory Biom...
Quality-of-Life...
Radiation Thera...
Veliparib
18 Years - National Cancer Institute (NCI) View Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer NCT05672095 Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Biopsy
Biospecimen Col...
Niraparib
Questionnaire A...
Selenium
18 Years - City of Hope Medical Center View Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02595892 Ovarian Serous ...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Berzosertib
Gemcitabine
Gemcitabine Hyd...
18 Years - National Cancer Institute (NCI) View PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02948101 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Anti-CSF1 Monoc...
Cyclophosphamid...
Laboratory Biom...
18 Years - M.D. Anderson Cancer Center View Intraperitoneal Infusion of ex Vivo-cultured Allogeneic NK Cells in Recurrent Ovarian Carcinoma Patients NCT03539406 Recurrent Ovari...
Recurrent Fallo...
Recurrent Prima...
UCB-NK cells
Chemotherapy
18 Years - 75 Years Radboud University Medical Center View EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT01489371 Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Undiffe...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Laboratory Biom...
PEG-PEI-cholest...
Pegylated Lipos...
18 Years - GOG Foundation View Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02595892 Ovarian Serous ...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Berzosertib
Gemcitabine
Gemcitabine Hyd...
18 Years - National Cancer Institute (NCI) View Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer NCT03552471 BRCA1 Gene Muta...
BRCA2 Gene Muta...
Folate Receptor...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Recurrent Uteri...
Recurrent Uteri...
Recurrent Uteri...
Platinum Resist...
Laboratory Biom...
Mirvetuximab So...
Pharmacokinetic...
Rucaparib Camsy...
18 Years - Ohio State University Comprehensive Cancer Center View Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer NCT02502266 Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Cediranib
Cediranib Malea...
Computed Tomogr...
Magnetic Resona...
Olaparib
Paclitaxel
Pegylated Lipos...
Questionnaire A...
Topotecan
Topotecan Hydro...
18 Years - National Cancer Institute (NCI) View p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer NCT02275039 Recurrent Ovari...
Recurrent Fallo...
Recurrent Prima...
modified vaccin...
gemcitabine hyd...
laboratory biom...
18 Years - City of Hope Medical Center View Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF NCT03604315 Breast Carcinom...
Fallopian Tube ...
Ovarian Carcino...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Solid Neoplasm
Computed Tomogr...
Computed Tomogr...
Fludeoxyglucose...
Fluorine F 18 F...
Positron Emissi...
Positron Emissi...
18 Years - M.D. Anderson Cancer Center View Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial NCT05554328 Recurrent Endom...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Biopsy
Biospecimen Col...
Bone Marrow Asp...
Computed Tomogr...
Echocardiograph...
Multigated Acqu...
Olaparib
Selumetinib Sul...
18 Years - National Cancer Institute (NCI) View Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer NCT04469764 Recurrent Endom...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Abemaciclib
Anastrozole
Letrozole
- Jonsson Comprehensive Cancer Center View Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02923739 Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Malignant Ovari...
Ovarian Adenoca...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Bevacizumab
Emactuzumab
Laboratory Biom...
Paclitaxel
Pharmacological...
18 Years - M.D. Anderson Cancer Center View Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT03579316 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Adavosertib
Olaparib
Ceralasertib
18 Years - M.D. Anderson Cancer Center View EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer NCT01489371 Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Undiffe...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Laboratory Biom...
PEG-PEI-cholest...
Pegylated Lipos...
18 Years - GOG Foundation View Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer NCT05231122 Ovarian Clear C...
Platinum-Sensit...
Recurrent Endom...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Ovari...
Recurrent Plati...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Recurrent Prima...
Anti-CD40 Agoni...
Bevacizumab
Pembrolizumab
Quality-of-Life...
Questionnaire A...
18 Years - Roswell Park Cancer Institute View Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer NCT02059265 Endometrial Cle...
Ovarian Clear C...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Recurrent Uteri...
Dasatinib
Laboratory Biom...
18 Years - National Cancer Institute (NCI) View Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer NCT01459380 Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
Bevacizumab
Carboplatin
Laboratory Biom...
Pegylated Lipos...
Veliparib
18 Years - National Cancer Institute (NCI) View TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors NCT02142803 Adult Glioblast...
Endometrial Cle...
Endometrial Ser...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Mucinou...
Ovarian Serous ...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Recurrent Uteri...
Solid Neoplasm
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Bevacizumab
Laboratory Biom...
Pharmacological...
Sapanisertib
18 Years - National Cancer Institute (NCI) View Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT01606241 Recurrent Breas...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Stage IIA Breas...
Stage IIA Fallo...
Stage IIA Ovari...
Stage IIB Breas...
Stage IIB Fallo...
Stage IIB Ovari...
Stage IIC Fallo...
Stage IIC Ovari...
Stage IIIA Brea...
Stage IIIA Fall...
Stage IIIA Ovar...
Stage IIIA Prim...
Stage IIIB Brea...
Stage IIIB Fall...
Stage IIIB Ovar...
Stage IIIB Prim...
Stage IIIC Brea...
Stage IIIC Fall...
Stage IIIC Ovar...
Stage IIIC Prim...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Cyclophosphamid...
Laboratory Biom...
Multi-epitope F...
18 Years - Mayo Clinic View Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer NCT02657928 Estrogen Recept...
Postmenopausal
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Recurrent Uteri...
Laboratory Biom...
Letrozole
Ribociclib
18 Years - Mayo Clinic View Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis NCT03508570 Malignant Perit...
Malignant Retro...
Metastatic Cerv...
Metastatic Endo...
Metastatic Fall...
Metastatic Mali...
Metastatic Ovar...
Metastatic Prim...
Peritoneal Carc...
Platinum-Refrac...
Platinum-Refrac...
Platinum-Refrac...
Platinum-Refrac...
Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Platinum-Resist...
Recurrent Cervi...
Recurrent Endom...
Recurrent Fallo...
Recurrent Malig...
Recurrent Ovari...
Recurrent Prima...
Stage IV Fallop...
Stage IV Ovaria...
Stage IV Primar...
Stage IVA Fallo...
Stage IVA Ovari...
Stage IVA Prima...
Stage IVB Cervi...
Stage IVB Fallo...
Stage IVB Ovari...
Stage IVB Prima...
Stage IVB Uteri...
Ipilimumab
Laboratory Biom...
Nivolumab
Pharmacokinetic...
18 Years - M.D. Anderson Cancer Center View Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer NCT00565851 Clear Cell Aden...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Mucinous Adenoc...
Ovarian Brenner...
Ovarian Clear C...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Ovarian Transit...
Ovarian Undiffe...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
Bevacizumab
Carboplatin
Docetaxel
Gemcitabine Hyd...
Laboratory Biom...
Paclitaxel
Quality-of-Life...
18 Years - National Cancer Institute (NCI) View Perfusion CT in Predicting Outcomes in Ovarian, Fallopian, or Peritoneal Cancer With Bevacizumab NCT03412630 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Computed Tomogr...
18 Years - Eastern Cooperative Oncology Group View Birinapant and Carboplatin in Treating Patients With Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02756130 High Grade Fall...
High Grade Ovar...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Birinapant
Carboplatin
Laboratory Biom...
Pharmacological...
18 Years - Jonsson Comprehensive Cancer Center View Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer NCT01459380 Ovarian Clear C...
Ovarian Endomet...
Ovarian Seromuc...
Ovarian Serous ...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Undifferentiate...
Bevacizumab
Carboplatin
Laboratory Biom...
Pegylated Lipos...
Veliparib
18 Years - National Cancer Institute (NCI) View Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF NCT03604315 Breast Carcinom...
Fallopian Tube ...
Ovarian Carcino...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Solid Neoplasm
Computed Tomogr...
Computed Tomogr...
Fludeoxyglucose...
Fluorine F 18 F...
Positron Emissi...
Positron Emissi...
18 Years - M.D. Anderson Cancer Center View APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion NCT04919629 Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Fallopian Tube ...
Ovarian Carcino...
Ovarian Clear C...
Ovarian Endomet...
Ovarian Serous ...
Primary Periton...
Primary Periton...
Primary Periton...
Primary Periton...
Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Bevacizumab
Biopsy
Biospecimen Col...
Pegcetacoplan
Pembrolizumab
Questionnaire A...
18 Years - Roswell Park Cancer Institute View Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT02312245 Recurrent Fallo...
Recurrent Ovari...
Recurrent Prima...
Bevacizumab
Gemcitabine Hyd...
Paclitaxel
Pegylated Lipos...
Topotecan Hydro...
18 Years - Mayo Clinic View